Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment

Launched by RYAN J. HALTER · Sep 8, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new device designed to help doctors determine if any cancerous tissue is left in the body during surgery to remove the prostate in men with prostate cancer. The device, called an Electrical Impedance Imaging (EII) probe, provides real-time information during the operation to ensure that all cancerous tissue is removed, which could improve treatment outcomes.

To participate in the trial, men aged 18 and older who have been diagnosed with prostate cancer and are scheduled for a specific type of surgery called robotic-assisted radical prostatectomy (RARP) may be eligible. However, individuals with certain conditions, like having a pacemaker or other implanted electrical devices, or those who have difficulty making decisions, cannot take part in the study. If you choose to join, you can expect to undergo the surgery as usual, with the added use of this new device to help ensure the best possible results for your health.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Clinical diagnosis of prostate cancer requiring RARP.
• • 2. Ability to understand and the willingness to sign a written informed consent document.
• • 3. Age ≥ 18 years old
• Exclusion Criteria:
• • 1. Adults with implanted electrical devices such as pacemakers
• • 2. Prisoners
• • 3. Adults with impaired decision-making capacity
• • 4. Any condition for which, in the opinion of the investigator, contraindicates study participation.